These trials are closed to recruitment but the follow-up phase is ongoing.
A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab), acalabrutinib (ACP-196) and ABT-199 (venetoclax) in patients with relapsed/refractory CLL (CLL2-BAAG protocol)
» more
A prospective, open-label, multicenter phase-II trial to evaluate the
efficacy and safety of a sequential regimen of bendamustine followed
by GA101 (obinutuzumab) and ABT-199 (venetoclax, GDC-0199)
followed by ABT-199 and GA101 maintenance in CLL patients
» more
A prospective, open-label, multicenter phase-II trial to evaluate the
efficacy and safety of a sequential regimen of bendamustine followed
by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101 maintenance in CLL patients
» more
A prospective, open-label, multicentre phase-II trial of ibrutinib plus venetoclax plus obinutuzumab in physically fit (CIRS ≤ 6 & normal creatinine clearance) and unfit (CIRS > 6 & creatinine clearance ≥ 50 ml/min) patients with previously untreated chronic lymphocytic leukemia (CLL) with TP53 deletion (17p-) and/or mutation
» more
A Placebo-Controlled, Double-Blind, Randomized, Multicenter,
Three Arm Phase III Trial to Compare the Efficacy and Safety of
Ibrutinib vs. Placebo in Previously Untreated Binet Stage A CLL
Patients with Risk of Early Disease Progression
» more
A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit patients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutation
» more
A prospective, open-label, multicenter randomized phase III trial to compare the efficacy and
safety of a combined regimen of obinutuzumab and GDC-0199 (ABT-199) versus obinutuzumab and
chlorambucil in previously untreated patients with CLL and coexisting medical conditions
» more
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the
efficacy and safety of lenalidomide (Revlimid®) as maintenance therapy for high-risk
patients with chronic lymphocytic leukemia following first-line therapy
» more
A prospective, multicenter, phase-II trial evaluating efficacy and
safety of Bendamustine + GA101 (BG) in patients with relapsed
CLL followed by maintenance therapy with GA101 for
responding patients
» more
Obinutuzumab containing conditioning regimen for CLL patients and patients with Richter`s transformation requiring an allogeneic stem cell transplantation
» more
A Prospective, Randomized, Open-Label, Multicenter, Phase 2 Trial to Evaluate
the Safety and Efficacy of the Combination of GS-4059 and Idelalisib with and without
Obinutuzumab in Subjects with Chronic Lymphocytic Leukemia
» more
A Prospective, Randomized, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of GS-4059 and Entospletinib with and without Obinutuzumab in Subjects with Chronic Lymphocytic Leukemia
» more